they should be easy to enter the market,ing india and israel should be able to enter it easily.'t explain it easily, perhaps your other guest can. they have a backlog of 4,000 drugs now and it takes almost two years to approve a new generic drug to come in. that allows incumbents to raise prices a little more than they would a few years ago. >> similar to people working in other markets, because the cost are shifted so that a patient won't necessarily pay the increase? >> to some degree, insurance which we all value and benefit, does insulate consumers from the full price of a product. so yes, to some degree. but i think it's important to make a distinction between sort of the generic market and the issues involved there and the branded-drug market. and as john mentioned i think on the branded side, prices are high, and sometimes launch prices will shock consumers when it's $100,000 for a break through drug. and again i think over time, the value of those drugs, in many cases, has been quite high, and most of the value has gone to society. on the generic side, i don't think that